| Description | BT8009 is a conjugate targeting Nectin-4, demonstrating a dissociation constant (Kd) of 2.5 nmol/L for the hNectin-4 ECD. This compound comprises a Nectin-4-specific bicyclic peptide, a cleavable linker, and MMAE. It is applicable in the study of advanced and metastatic urothelial cancer [1]. |
| In vitro | BT8009 在 MDA-MB-468 细胞膜上自然表达的 Nectin-4 与之结合，展现出的“表观亲和性”浓度为 12.9 nmol/L [1]。 |
| In vivo | BT8009（剂量为1、2、3 mg/kg；静脉注射方式，每周一次，共5次）在三阴性乳腺癌和非小细胞肺癌的小鼠异种移植模型中展现了其抗肿瘤活性[1]。在大鼠中，BT8009的最大耐受剂量（MTD）为5 mg/kg，而在非人类灵长动物中为1.5 mg/kg，基于5周的剂量给药计划[1]。 |
| molecular weight | N/A |
| Molecular formula | C194H283N45O50S4 |
| CAS | 2748001-89-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |